Biolife Solutions INC 8-K filings

BioLife Solutions announced a 21% year-over-year revenue increase for Q2 2026, alongside a significant acquisition agreement with Repligen expected to close in Q4 2026.

BioLife Solutions announces its merger with Repligen Corporation, aiming to accelerate growth and enhance bioprocessing capabilities.

Repligen Corporation announced its definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion, aiming to expand its cell therapy capabilities.

BioLife Solutions presented an investor deck on June 3, 2026, detailing its industry-leading position in biopreservation and cell processing tools for cell-based therapies, showcasing strong revenue growth and strategic portfolio optimization.

BioLife Solutions, a leading provider of biopreservation and cell processing tools, issued an investor presentation detailing its strategic refocus, strong financial performance in 2025, and positive outlook for 2026.

BioLife Solutions announced robust fourth quarter and full year 2025 financial results, driven by its focused cell processing strategy, and provided optimistic 2026 guidance.

BioLife Solutions announced preliminary unaudited Q4 and full-year 2025 revenue from continuing operations, exceeding its raised guidance and signaling future growth.

BioLife Solutions, Inc. announced that Chief Quality and Operations Officer Karen Foster will retire effective March 31, 2026.

BioLife Solutions, a leading provider of biopreservation and processing tools, projects 27-29% organic revenue growth for FY 2025, driven by its embedded position in the expanding cell-based therapy market.

BioLife Solutions announced robust third-quarter 2025 financial results, driven by a 33% increase in Cell Processing revenue, and raised its full-year revenue guidance after divesting its evo cold chain logistics business.

BioLife Solutions, Inc. shareholders re-elected all seven directors, approved executive compensation, and ratified Grant Thornton LLP as auditors at their 2025 annual meeting.

BioLife Solutions reports strong second-quarter revenue growth driven by cell processing, prompting an upward revision of its full-year 2025 financial outlook.

BioLife Solutions announces a 30% increase in total revenue for Q1 2025, driven by a 33% surge in cell processing revenue.

BioLife Solutions appoints Catherine Coste to its board of directors and as chair of the audit committee, effective March 18, 2025.

BioLife Solutions announces positive Q4 and full year 2024 financial results, driven by cell processing revenue growth, and provides optimistic 2025 revenue guidance.

BioLife Solutions reports a 31% year-over-year increase in preliminary Q4 revenue and exceeds full-year cell processing revenue guidance, driven by growth in the cell and gene therapy market.

BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors, effective January 2, 2025.

BioLife Solutions has completed the sale of its Custom Biogenic Systems (CBS) business to Standex International Corporation for approximately $6.1 million.

BioLife Solutions announced a 43% year-over-year increase in Cell Processing revenue for Q3 2024 and raised its full-year guidance for this segment.

BioLife Solutions has finalized the sale of its SciSafe subsidiary to Subzero Purchaser Corp. for a total of $73 million.

BioLife Solutions has revised its second-quarter financial results to reflect a reduction in stock compensation expense and has increased its full-year revenue guidance.

BioLife Solutions announced positive second-quarter results, including an 11% sequential increase in cell processing revenue and an improved full-year revenue outlook.

BioLife Solutions successfully held its 2024 annual meeting, re-electing all nominated directors, approving executive compensation, and ratifying the appointment of Grant Thornton LLP as its auditor.

BioLife Solutions announced its first quarter 2024 financial results, showcasing a 10% sequential increase in cell processing revenue and the divestiture of its GCI freezer business.

BioLife Solutions has finalized the sale of its Global Cooling subsidiary for $1, while also amending its loan agreement with Silicon Valley Bank.

BioLife Solutions has sold its Global Cooling subsidiary for $1, resulting in a workforce reduction of approximately 47 employees and expected cost savings.

BioLife Solutions reported a decrease in fourth-quarter revenue but saw growth in its cell processing segment and is divesting its freezer business to focus on higher-margin opportunities.